▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #928 by analyst upside · 2026-11-13
SVRA
Savara Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+134.2%
implied upside to consensus target
Current Price $4.72
Consensus Target $11.06
Bull Target $16.0
Bear Target $9.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
0
Sell
0
52-Week Low $4.03
52-Week High $7.0
YTD Return -16.3%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.60
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.03
52-Week High $7.0
Current Price $4.72
Bear Target $9.0
Bull Target $16.0
● Now $4.72 ● Target $11.06
TRADING DATA
Avg Volume 2.2M
YTD Return -16.3%
Analyst Count 9
Consensus Buy
Upside to Target +134.2%
Last Updated 2026-11-13

ANALYST SUMMARY

Savara Inc. (SVRA) is currently trading at $4.72 with a Wall Street consensus price target of $11.06, implying potential upside of 134.2% over the next 12 months. 9 analysts currently cover SVRA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $9.0.

SVRA operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 16.3% year-to-date and is currently trading near the lower end of its 52-week range of $4.03 – $7.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

VOR +101.9%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy
NUTX +83.0%
Nutex Health Inc.
$1B · P/E 7.4x · Buy
GTBIF +133.1%
Green Thumb Industries Inc.
$1B · P/E 14.8x · Buy
DMRA +112.1%
Damora Therapeutics, Inc.
$1B · P/E 12.9x · Buy
INVA +83.4%
Innoviva, Inc.
$1B · P/E 8.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SVRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ● Initiated
Overweight 2026-10-07 43% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-12-23 31% win rate (48 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2025-12-18 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2025-11-14 14% win rate (7 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2025-11-13 Building track record
JMP Securities - Reiterated
Market Outperform → Market Outperform 2025-10-23 Building track record
Guggenheim - Reiterated
Buy → Buy 2025-09-09 62% win rate (8 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-09-08 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →